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Anti-MAG demyelinating neuropathy is diﬃcult to treat. All immunotherapies have failed
except for rituximab, a chimeric B-cell–depleting monoclonal antibody against CD20, that
helps up to 40% of patients based on 2 controlled and several uncontrolled series.1–3 Because
the majority of these patients are left disabled, stronger anti–B-cell agents might be promising.

MORE ONLINE

We describe clinical response and autoantibody changes after treatment with obinutuzumab
(Gazyva), a new generation of humanized anti-CD20 monoclonal antibodies, in 2 patients with
anti-MAG neuropathy who continued to worsen despite multiple courses of rituximab. Obinutuzumab, approved for chronic lymphocytic leukemia (CLL), exerts greater peripheral and
lymphoid B-cell depletion4 and might be more eﬀective in rituximab-refractory patients.

Class of Evidence

Criteria for rating
therapeutic and diagnostic
studies
NPub.org/coe

Classiﬁcation of evidence
This is a single observational study without controls and provides Class IV evidence that
obinutuzumab is safe to use in patients with IgM anti-MAG demyelinating neuropathy.

Patients and treatments
Patient 1
A 71-year-old man developed feet paresthesias that progressed in 4 years to bilateral foot drop.
Workup revealed distal demyelinating neuropathy, a benign IgMκ monoclonal gammopathy,
elevated IgM levels, and high-titer anti-MAG antibodies (table). The gammopathy was benign
including normal bone marrow biopsy. He received 3 monthly courses of IVIG without beneﬁts. Rituximab, 2 g, was ineﬀective without aﬀecting the IgM level or anti-MAG titers while his
weakness continued to worsen. Obinutuzumab was then administered in 6 cycles over 6
months, as per the CLL protocol, as follows: day 1: 100 mg; day 2: 900 mg; days 8 and 18:
1,000 mg each; and 1,000 mg thereafter monthly for 5 months.
Patient 2
A 65-year-old man, developed distal leg numbness and paresthesias 13 years ago following
successful therapy for colorectal cancer. The neuropathic symptoms gradually worsened with
sensory ataxia and muscle weakness. Workup revealed a demyelinating neuropathy, an IgMκ
gammopathy, normal bone marrow biopsy, and high-titer anti-MAG antibodies (table). His
symptoms transiently improved with oral corticosteroids and IVIG. Over the following 7 years,
he received 5 courses of rituximab, 2 g every year. His gait and stamina improved after the ﬁrst 2
treatments, but there was no further beneﬁt. He gradually progressed with more weakness,
requiring MAFOs and canes for ambulation, and prominent hand tremors. The IgMκ spike and
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Table IgM levels and anti-MAG antibody titers before and after treatment with obinutuzumab in 2 patients with anti-MAG
neuropathy
IgM levels
(normal 40–230 mg/dL)

IgM monoclonal
spike

Anti-MAG titers by EIA
(normal ≤ 1:1600 units)

Before obinutuzumab

524 mg/dL

Present

>1:102,400

After obinutuzumab

229 mg/dL

Present

<1:1,600 (normalized)

Before obinutuzumab

420 mg/dL

Present

>1:102,400

After obinutuzumab

173 mg/dL

Present

<1:1,600 (normalized)

Patients
Patient 1

Patient 2

high anti-MAG antibody titers persisted. Because of severe
disease worsening and continuing disability not responding
anymore to rituximab, he was treated with obinutuzumab,
administered for 6 months as described above.

Results
There was no clinical improvement or worsening in the
patients’ neuropathic symptoms 6 and 12 months after
treatment with obinutuzumab. In patient 1, the neurologic
deﬁcits remained unchanged several months after therapy.
Patient 2, 1 year after therapy, showed signs of progression
in pace consistent with his pretreatment course; no accelerated worsening related to obinutuzumab was observed.
Both patients tolerated the treatment well. Except for
transient mild thrombocytopenia, there were no complications during the administration or the follow-up period.
Despite no clinical beneﬁts, however, the IgM levels normalized and remained normal up to a year after obinutuzumab in
both patients (table). Of interest, the anti-MAG antibody titers,
6 months after treatments, were also normalized and remained
low up to 12 months; the IgMκ spike, however, remained
unchanged without discernible diﬀerences in the light chain
(table). In patient 2, 1 year after obinutuzumab, the anti-MAG
titers started to rise, reaching now >70,000 units.

Discussion
The clinical success of ﬁrst-generation glycoengineered type-I,
anti–CD20-mediated, B-cell–depleting, monoclonal antibodies
in autoimmune neurologic and rheumatological disorders has
provided the rationale for using more potent next-generation
anti-CD20 agents. For example, ocrelizumab and ofatumumab
seem more eﬀective than rituximab in progressive and relapsing
MS.5,6 Obinutuzumab, a third-generation, glycoengineered
type-II, humanized anti-CD20 monoclonal antibody approved
for CLL, has increased binding aﬃnity to the Fc receptor on
B cells and enhanced complement and antibody-dependent
cytotoxicity resulting in extensive B-cell lysis of peripheral
B cells, including some within the lymphoid tissues; because it
2

also aﬀects IL-6 production, it is expected to cause more sustained depletion of memory B cells and aﬀect antibody production. These eﬀects prompted us to evaluate its eﬃcacy in
patients with rituximab-refractory anti-MAG–mediated neuropathy.3 Obinutuzumab, administered for 6 months, was safe
but did not improve the patients’ symptomatology even up to
a year of follow-up. In contrast to rituximab, however, it normalized the IgM level and anti-MAG antibody titers (table).
This observation suggests an eﬀect beyond B-cell depletion;
B cells play a key role in antigen presentation, complement
activation, and cytokine production, such as IL-1, IL-6, and IL10, that aﬀect immunoregulatory B and T cells and antibody
production by plasma cells.7 These preliminary results, even in
a limited number of 2 patients, suggest that the IgM anti-MAG
antibodies, despite being pathogenic,8 do not seem to correlate
with clinical response. Whether this is related to our patients’
advanced disease and severe axonal degeneration or to ineﬀectiveness of obinutuzumab is unclear. The good tolerance
of the drug, however, the more profound induction of B-cell
depletion, and eﬀect on antibodies, as demonstrated with
normalization of IgM and anti-MAG titers, suggest that obinutuzumab might still be considered as an early treatment of
this diﬃcult-to-treat neuropathy.
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